These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7752493)

  • 1. [Secondary and tertiary hyperparathyroidism].
    Kuriyama M; Yang M
    Nihon Rinsho; 1995 Apr; 53(4):965-7. PubMed ID: 7752493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets.
    Savio RM; Gosnell JE; Posen S; Reeve TS; Delbridge LW
    Arch Surg; 2004 Feb; 139(2):218-22. PubMed ID: 14769584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parathyroidectomy in end-stage renal disease: perioperative management of calcium-phosphorus balance].
    Vallée M; Lalumière G; Déziel C; Quérin S; Madore F
    Ann Biol Clin (Paris); 2007; 65(1):71-6. PubMed ID: 17264042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
    Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTH.
    Mahajan A; Narayanan M; Jaffers G; Concepcion L
    Hemodial Int; 2009 Oct; 13(4):547-50. PubMed ID: 19493022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroidectomy in the treatment of secondary hyperparathyroidism in chronic renal failure.
    Kostakis A; Vaiopoulos G; Kostantopoulos K; Zavos G; Bocos I; Sgouromalis S
    Int Surg; 1997; 82(1):85-6. PubMed ID: 9189811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
    Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
    Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of percutaneous ethanol injection therapy on subsequent parathyroidectomy.
    Chen HH; Hsu MT; Wu CJ; Chen YW; Yang TL
    Am J Surg; 2008 Aug; 196(2):155-9. PubMed ID: 18513687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary hyperparathyroidism in chronic renal failure.
    Malmaeus J
    Scand J Urol Nephrol Suppl; 1983; 70():1-63. PubMed ID: 6351238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Secondary hyperparathyroidism].
    Diaconescu MR; Costea I; Terinte R; Diaconescu S; Covic M; Zbranca E
    Chirurgia (Bucur); 1995; 44(1):27-34. PubMed ID: 7496211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of calcium refilling post-parathyroidectomy in end-stage renal disease.
    Cozzolino M; Gallieni M; Corsi C; Bastagli A; Brancaccio D
    J Nephrol; 2004; 17(1):3-8. PubMed ID: 15151253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.
    Komaba H; Shiizaki K; Fukagawa M
    Expert Opin Biol Ther; 2010 Dec; 10(12):1729-42. PubMed ID: 21058933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for uremic secondary hyperparathyroidism.
    Torres PU; Prié D; Beck L; Friedlander G
    J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current advances in the therapy of secondary hyperparathyroidism and osteitis fibrosa.
    Llach F; Nikakhtar B
    Miner Electrolyte Metab; 1991; 17(4):250-5. PubMed ID: 1813787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction.
    Yendt ER; Kovacs KA; Jones G
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):855-63. PubMed ID: 18419790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
    J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management.
    Mittendorf EA; Merlino JI; McHenry CR
    Am Surg; 2004 Feb; 70(2):114-9; discussion 119-20. PubMed ID: 15011912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.